Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Benign Prostatic Hyperplasia - Drugs In Development, 2022, provides an overview of the Benign Prostatic Hyperplasia (Male Health) pipeline landscape.
Benign Prostatic Hyperplasia (BPH) is a non-cancerous enlargement of the prostate, a small gland that encircles the urethra in males and produces a fluid that makes up part of semen. Symptoms include decreased strength of the urine stream, dribbling after urination, pain during urination, waking at night to urinate, difficulty starting a urine stream. Treatment options for BPH include surgery and medications.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Benign Prostatic Hyperplasia - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Benign Prostatic Hyperplasia (Male Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Benign Prostatic Hyperplasia (Male Health) pipeline guide also reviews of key players involved in therapeutic development for Benign Prostatic Hyperplasia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 4, 4, 3, 1, 6, 2 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Benign Prostatic Hyperplasia (Male Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Benign Prostatic Hyperplasia (Male Health).
- The pipeline guide reviews pipeline therapeutics for Benign Prostatic Hyperplasia (Male Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Benign Prostatic Hyperplasia (Male Health) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Benign Prostatic Hyperplasia (Male Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Benign Prostatic Hyperplasia (Male Health)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Benign Prostatic Hyperplasia (Male Health).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Benign Prostatic Hyperplasia (Male Health) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
'
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Benign Prostatic Hyperplasia - Overview
Benign Prostatic Hyperplasia - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Benign Prostatic Hyperplasia - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Benign Prostatic Hyperplasia - Companies Involved in Therapeutics Development
AiViva BioPharma Inc
Aphios Corp
Aquestive Therapeutics Inc
ASKA Pharmaceutical Holdings Co Ltd
BCWorld Pharm Co Ltd
Boryung Pharmaceutical Co Ltd
Chengdu Dikang Pharmaceuticals Co Ltd
Chong Kun Dang Pharmaceutical Corporation
Curadis GmbH
DongKoo Bio & Pharma Co Ltd
Dongkook Pharmaceutical Co Ltd
GemVax & KAEL Co Ltd
Genu Pharma Co Ltd
Geropharm
Hanmi Pharmaceuticals Co Ltd
Jiangsu Kangyuan Pharmaceutical Co Ltd
Kwang Dong Pharmaceutical Co Ltd
Nymox Pharmaceutical Corp
Sentan Pharma Inc
ValiRx Plc
Veru Inc
XuanZhu Biological Technology Co Ltd
Benign Prostatic Hyperplasia - Drug Profiles
(dutasteride + tadalafil) - Drug Profile
Product Description
Mechanism Of Action
(dutasteride + tamsulosin hydrochloride) - Drug Profile
Product Description
Mechanism Of Action
(finasteride + tadalafil) - Drug Profile
Product Description
Mechanism Of Action
(mirabegron + tamsulosin hydrochloride) - Drug Profile
Product Description
Mechanism Of Action
AIV-007 - Drug Profile
Product Description
Mechanism Of Action
AKP-009 - Drug Profile
Product Description
Mechanism Of Action
BCWPE-004 - Drug Profile
Product Description
Mechanism Of Action
BR-9006 - Drug Profile
Product Description
Mechanism Of Action
CKD-843 - Drug Profile
Product Description
Mechanism Of Action
CR-1447 - Drug Profile
Product Description
Mechanism Of Action
DDCI-01 - Drug Profile
Product Description
Mechanism Of Action
Drug for Benign Prostatic Hyperplasia and Overactive Bladder - Drug Profile
Product Description
Mechanism Of Action
fadanafil - Drug Profile
Product Description
Mechanism Of Action
fexapotide triflutate - Drug Profile
Product Description
Mechanism Of Action
GP-20051 - Drug Profile
Product Description
Mechanism Of Action
KD-304 - Drug Profile
Product Description
Mechanism Of Action
KKM-1202 - Drug Profile
Product Description
Mechanism Of Action
Quinolixin - Drug Profile
Product Description
Mechanism Of Action
S-0131632 - Drug Profile
Product Description
Mechanism Of Action
SP-0051 - Drug Profile
Product Description
Mechanism Of Action
Sperol - Drug Profile
Product Description
Mechanism Of Action
tadalafil - Drug Profile
Product Description
Mechanism Of Action
tamsulosin SR - Drug Profile
Product Description
Mechanism Of Action
tertomotide - Drug Profile
Product Description
Mechanism Of Action
VAL-301 - Drug Profile
Product Description
Mechanism Of Action
Benign Prostatic Hyperplasia - Dormant Projects
Benign Prostatic Hyperplasia - Discontinued Products
Benign Prostatic Hyperplasia - Product Development Milestones
Featured News & Press Releases
Dec 13, 2021: Veru announces FDA approval of ENTADFI, a new treatment for benign prostatic hyperplasia
Feb 23, 2021: Veru submits new drug application for proprietary TADFIN for BPH
Jul 10, 2020: Ministry OKs Dongkook's P3 trial into benign prostatic hyperplasia treatment
Oct 23, 2019: GV1001, shows efficacy as a treatment for Benign Prostatic Hyperplasia
Jun 26, 2019: Veru announces successful completion of pre-NDA meeting with FDA for tadfin (tadalafil 5mg and finasteride 5mg) combination for the treatment of benign prostatic hyperplasia
Apr 05, 2019: Gemvax & Kael’s wins nod for P3 trial of benign prostatic hyperplasia treatment
Jan 31, 2019: ValiRx received Russian Federation & Chinese patent grant allowances for therapeutic compound, VAL301
Jan 14, 2019: Veru Plans to Submit NDA in 2019
Dec 03, 2018: Veru announces first patient dosed in bioequivalence clinical trial for combination Tadalafil - Finasteride tablet for benign prostatic hyperplasia
Apr 16, 2018: GemVax & KAEL Announces Positive Phase 2 Data on GV1001 for Prostate Hyperplasia
Dec 14, 2016: CFDA Granted Approval forPhase I/II/III Clinical Trials of Sihuan Pharmaceutical’s Internally Developed Innovative Patented New Drug - Fadanafil
Jul 26, 2010: Aphios Awarded United States Patent For Compositions And Methods For Inhibiting 5-Alpha Reductase
Mar 02, 2010: Impax Receives Final FDA Approval For Generic FLOMAX 0.4mg Capsules
Oct 07, 2009: Impax Laboratories Settles Pending Litigation for FLOMAX
Oct 05, 2009: Impax Laboratories Receives Tentative FDA Approval for Generic FLOMAX 0.4mg Capsules
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Benign Prostatic Hyperplasia, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Benign Prostatic Hyperplasia - Dormant Projects, 2022
Benign Prostatic Hyperplasia - Discontinued Products, 2022
List of Figures
Number of Products under Development for Benign Prostatic Hyperplasia, 2022
Number of Products under Development by Companies, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022
